Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-blind, Placebo-controlled, Single-center Study Investigating the Dose of Human Anti-Human Platelet Antigen (HPA)-1a Immune Globulin (NAITgam) Needed to Eliminate HPA-1a Positive Platelets Transfused to HPA-1a Negative Healthy Male Volunteers

Next Previous
Trial Profile

A Single-blind, Placebo-controlled, Single-center Study Investigating the Dose of Human Anti-Human Platelet Antigen (HPA)-1a Immune Globulin (NAITgam) Needed to Eliminate HPA-1a Positive Platelets Transfused to HPA-1a Negative Healthy Male Volunteers

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 12 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RLYB 211 (Primary)
  • Indications Neonatal alloimmune thrombocytopenia
  • Focus First in man; Pharmacokinetics; Proof of concept
  • Sponsors Rallybio

Most Recent Events

  • 06 Apr 2023 According to a Rallybio media release, given the advantages of small volume subcutaneous dosing of RLYB212 as compared to RLYB211 and the expected manufacturing and supply efficiencies for RLYB212, the company announced in March 2023 that it will not continue development of RLYB211.
  • 06 Apr 2023 Status changed from suspended to discontinued, according to a Rallybio Media Release.
  • 06 Apr 2023 Results presented in the Rallybio Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top